Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco from January 13-16, 2025.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver a corporate update presentation on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in the Elizabethan B room. The presentation will be available via live webcast on the company’s website, with a replay accessible for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK), un’azienda biotecnologica focalizzata sullo sviluppo di terapie mirate ai recettori della superfamiglia TNF per malattie infiammatorie e immunitarie, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. L’evento si svolgerà a San Francisco dal 13 al 16 gennaio 2025.
Dr. Taylor Schreiber, CEO di Shattuck, presenterà un aggiornamento aziendale il 16 gennaio 2025, alle 7:30 a.m. PT presso il The Westin St. Francis nella sala Elizabethan B. La presentazione sarà disponibile tramite webcast dal vivo sul sito web dell’azienda, con una registrazione accessibile per un massimo di 30 giorni successivi.
Shattuck Labs (NASDAQ: STTK), una empresa de biotecnología centrada en el desarrollo de terapias dirigidas a los receptores de la superfamilia TNF para enfermedades inflamatorias y relacionadas con el sistema inmunológico, anunció su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El evento se llevará a cabo en San Francisco del 13 al 16 de enero de 2025.
El Dr. Taylor Schreiber, CEO de Shattuck, ofrecerá una presentación sobre la actualización corporativa el 16 de enero de 2025, a las 7:30 a.m. PT en The Westin St. Francis, en la sala Elizabethan B. La presentación estará disponible a través de un webcast en vivo en el sitio web de la empresa, con una grabación accesible durante hasta 30 días después.
Shattuck Labs (NASDAQ: STTK)는 염증 및 면역 관련 질병을 위한 TNF 초단체 수용체를 표적으로 하는 치료제를 개발하는 데 집중하는 생명공학 회사로, 제43회 연례 JP Morgan Healthcare 컨퍼런스에 참여한다고 발표했습니다. 이번 행사는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열릴 예정입니다.
Shattuck의 CEO인 Dr. Taylor Schreiber는 2025년 1월 16일 오전 7시 30분 PT에 The Westin St. Francis의 Elizabethan B 룸에서 기업 업데이트 발표를 할 것입니다. 발표는 회사 웹사이트에서 실시간 웹캐스트로 제공되며, 이후 최대 30일 동안 다시 볼 수 있습니다.
Shattuck Labs (NASDAQ: STTK), une entreprise biotechnologique axée sur le développement de thérapeutiques ciblant les récepteurs de la superfamille TNF pour les maladies inflammatoires et liées au système immunitaire, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. L’événement se déroulera à San Francisco du 13 au 16 janvier 2025.
Le Dr. Taylor Schreiber, PDG de Shattuck, fera une présentation de mise à jour de l’entreprise le 16 janvier 2025, à 7h30 PT au The Westin St. Francis dans la salle Elizabethan B. La présentation sera disponible en direct via webcast sur le site internet de l’entreprise, avec un replay accessible pendant jusqu’à 30 jours après.
Shattuck Labs (NASDAQ: STTK), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapeutika konzentriert, die auf TNF-Superfamilienrezeptoren für entzündliche und immunologische Krankheiten abzielen, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Die Veranstaltung findet vom 13. bis 16. Januar 2025 in San Francisco statt.
Dr. Taylor Schreiber, CEO von Shattuck, wird am 16. Januar 2025 um 7:30 Uhr PT im The Westin St. Francis im Raum Elizabethan B eine Unternehmensaktualisierung präsentieren. Die Präsentation wird live im Webcast auf der Unternehmenswebsite verfügbar sein, mit einer Wiederholung, die bis zu 30 Tage danach zugänglich ist.
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025.
Conference Details
Format: Presentation and one-on-one meetings
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 16, 2025
Time: 7:30 a.m. PT
Location: The Westin St. Francis, San Francisco, California
Room: Elizabethan B
A live webcast of the presentations will be available on the Events and Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) presenting at the 2025 J.P. Morgan Healthcare Conference?
Shattuck Labs will present on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in San Francisco.
How long will STTK’s J.P. Morgan Healthcare Conference presentation replay be available?
The webcast replay will be archived and available for up to 30 days following the presentation date.
What is the focus of Shattuck Labs’ (STTK) therapeutic development?
Shattuck Labs focuses on developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for treating inflammatory and immune-related diseases.
Where can investors watch Shattuck Labs’ (STTK) J.P. Morgan Healthcare Conference presentation?
Investors can watch the live webcast through the Events and Presentations section of the Company’s website.
